Breast Cancer | Specialty

The OncLive Breast Cancer condition center page is a comprehensive resource for clinical news and expert insights on various types of breast cancer, including those that are triple negative, hormone receptor positive, and/or HER2 positive. This page features news articles, interviews in written and video format, and podcasts that focus on treatment advances and ongoing research in breast cancer.

Dr. Muss on the Use of Metronomic Chemotherapy in Metastatic Breast Cancer

March 16th 2023

Hyman B. Muss, MD, discusses the use of metronomic chemotherapy in metastatic breast cancer.

Evolution in the Field of HR+ Breast Cancer Management

March 16th 2023

Closing out their discussion on HR+ breast cancer management, expert panelists share their excitement for the evolving treatment paradigm.

Dr. Sharma on Optimal Systemic Therapy for Early-Stage TNBC

March 15th 2023

Priyanka Sharma, MD, discusses updates in optimal systemic therapy strategies in early-stage triple-negative breast cancer.

Dr. Patel on the Association Between Ki-67 and Race in Early Breast Cancer

March 14th 2023

Rima Patel, MD, discusses the associations between the 21-gene oncotype DX recurrence score, Ki-67, and race in early-stage breast cancer.

Dr. D'Ambrosio on the Rationale of Accelerated Partial Breast Irradiation in HR+ Breast Cancer

March 14th 2023

David D'Ambrosio, MD, discusses the benefit of utilizing adjuvant accelerated partial breast irradiation, as well as a phase 2 trial investigating robotic stereotactic adjuvant accelerated partial breast irradiation for hormone receptor–positive, postmenopausal, early-stage breast cancer.

Dr. Rimm on the Use of Multiplex Spatial Proteomic Profiling in Breast Cancer

March 14th 2023

David Rimm, MD, PhD, discusses both the use and advantages of utilizing multiplex spatial proteomic profiling in breast cancer.

Dr. Johnson on the Importance of Diverse Representation in Breast Cancer Clinical Trials

March 10th 2023

Nathalie McDowell Johnson, MD, FACS, discusses the importance of diverse representation in breast cancer clinical trials.

Dr. Kaklamani on CDK4/6 Inhibition Prior to Elacestrant in ER+/HER2– Breast Cancer

March 10th 2023

Virginia Kaklamani, MD, discusses the utilization of elacestrant following treatment with CDK4/6 inhibitors in patients with estrogen receptor-positive, HER2-negative metastatic breast cancer.

Dr. Nair on Using Yoga to Improve Quality of Life in Patients Undergoing Breast Cancer Treatments

March 10th 2023

Nita Nair, MBBS, DNB, MCh, discusses research evaluating the role of yoga as a way to improve the quality of life of patients undergoing breast cancer treatments.

Other Treatment Modalities for HR+ Metastatic Breast Cancer

March 9th 2023

Comprehensive discussion on novel treatment modalities in HR+ metastatic breast cancer and insight to when it is appropriate to select these agents.

HR+ Metastatic Breast Cancer: Optimal Selection of Endocrine Partners

March 9th 2023

Shared insight on the selection of endocrine partners while managing patients in the relapsed/refractory setting of HR+ metastatic breast cancer.

Palbociclib Plus Aromatase Inhibitor Therapy Provides Real-World Benefit in Older Patients With HR+/HER2– Metastatic Breast Cancer

March 7th 2023

Palbociclib plus an aromatase inhibitor improved real-world data for progression-free survival, overall survival, and time to chemotherapy compared with an aromatase inhibitor alone in patients 75 years and older with hormone receptor–positive, HER2-negative advanced/metastatic breast cancer.

ADCs Advance HR+/HER2– Breast Cancer Treatment Paradigm

March 7th 2023

As more antibody-drug conjugates emerge and investigators foresee fam-trastuzumab deruxtecan-nxki moving forward in lines of treatment for metastatic disease, the treatment landscape of hormone receptor–positive, HER2-negative breast cancer continues to expand and shift.

Advice for Community Physicians on Managing HER2+ Breast Cancer

March 7th 2023

Closing out their review on treatment strategies for HER2-expressing breast cancer, panelists share practical advice for the community setting.

Lasofoxifene May Improve Vaginal/Vulvar Symptoms in Postmenopausal ER+/HER2–, ESR1-Mutated Breast Cancer

March 6th 2023

Lasofoxifene improved vaginal/vulvar symptoms compared with fulvestrant in premenopausal patients with locally advanced or metastatic estrogen receptor–positive/HER2-negative breast cancer harboring an ESR1 mutation.

Metronomic Chemotherapy Represents Late Treatment Option for Some Patients With Metastatic Breast Cancer

March 6th 2023

Hyman B. Muss, MD, discusses the potential benefits of metronomic chemotherapy and which patients with metastatic breast cancer could be candidates, as well as how to approach end-of-life conversations and decisions for patients.

Unmet Needs and the Future of HER2+ Breast Cancer Treatment

March 6th 2023

The panel closes their discussion by summarizing the most exciting recent advances in HER2+ breast cancer, the future of treatment, and unmet needs that must be addressed.

Emerging Data and Investigational Agents in HER2+ mBC

March 6th 2023

The panel highlights emerging data from SABCS 2022 on investigational agents being explored for HER2+ mBC treatment.

Use of MRI for Surveillance of Brain Metastases in Patients with HER2+ mBC

March 6th 2023

The panel discusses the management of patients with HER2+ mBC with asymptomatic brain mets and shares their thoughts on the use of surveillance brain MRI in this setting.

Real-World Outcomes With Sacituzumab Govitecan Match ASCENT in Single-Center Study

March 5th 2023

In a single-center study, investigators assessed real-world outcomes in patients with metastatic metastatic triple-negative breast cancer treated with the antibody-drug conjugate sacituzumab govitecan-hziy.